Agenus Inc. (AGEN)
| Market Cap | 277.02M +65.1% |
| Revenue (ttm) | 123.87M +24.5% |
| Net Income | 64.39M |
| EPS | 1.93 |
| Shares Out | 44.75M |
| PE Ratio | 3.20 |
| Forward PE | 13.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,333,435 |
| Open | 5.53 |
| Previous Close | 5.53 |
| Day's Range | 5.46 - 6.23 |
| 52-Week Range | 2.71 - 8.70 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 30.00 (+384.65%) |
| Earnings Date | Aug 10, 2026 |
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ... [Read more]
Financial Performance
In 2025, Agenus's revenue was $114.20 million, an increase of 10.37% compared to the previous year's $103.46 million. Losses were -$101,000, -99.96% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price target is $30.0, which is an increase of 384.65% from the latest price.
News
Agenus Registration statement: Registration filing
Agenus filed a registration statement on July 20, 2026, providing details about a securities offering with the SEC.
Agenus files to sell 2.13M shares of common stock for holders
06:05 EDT Agenus (AGEN) files to sell 2.13M shares of common stock for holders
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials e...
Why Is Agenus (AGEN) Stock Up Today?
Agenus stock was up on Monday alongside a new funding announcement and a price target increase.
Agenus price target raised to $30 from $23 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Agenus (AGEN) to $30 from $23 and keeps a Buy rating on the shares. The company announced a strategic…
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
Agenus (AGEN) announced earlier that across NEST and UNICORN, two independent Phase 2 studies evaluating neoadjuvant BOT+BAL in MSS colorectal cancer, BOT+BAL has produced deep, durable responses, inc...
Agenus Transcript: Investor update
A major strategic shift prioritizes the neoadjuvant BOT/BAL program for MSS colon cancer, backed by strong phase II data and FDA-aligned phase III trial design. Up to $340 million in financing secures operations through 2031, targeting a large, underserved market with significant clinical and commercial potential.
Agenus Press release: Investor update
Agenus issued a press release on July 13, 2026, disclosing material business information to investors.
Agenus Slides: Investor update
Agenus has posted slides in relation to its latest quarterly earnings report, which was published on July 13, 2026.
Agenus announces $340M private placement
Agenus (AGEN) announced that it has entered into a securities purchase agreement for a private placement of approximately $85M in upfront gross proceeds, before the deduction of private placement expe...
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a pri...
Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI
Agenus (AGEN) announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab, an Fc-enhanced multifunctional anti-CTLA-4 antibody, plus balstilimab, an ant...
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01...
Agenus announces three-year survival data from Phase 1b BOT+BAL study
Agenus (AGEN) announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab, an Fc-enhanced multifunctional anti-CTLA-4 antibody, plus balstilimab, an anti-PD-1 antibody, in...
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (B...
Agenus Transcript: AGM 2026
The meeting approved all proposals, including director elections, plan amendments, and auditor ratification. Strategic focus remains on advancing BOT/BAL immunotherapy, expanding access, and strengthening financials, with new trials and regulatory submissions planned in the coming quarters.
Agenus Announces Virtual 2026 Annual Shareholders Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:...
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligenc...
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ASCO2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study ...
Agenus announces publication of Phase 1b BOT+BAL data
Agenus (AGEN) announced the publication of Phase 1b data evaluating botensilimab, an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab, an anti-PD-1 antibody, in patients with treatmen...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), a...
Agenus Proxy statement: Proxy filing
Agenus filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
Agenus reports Q1 revenue $33.7M vs. $24.1M last year
“First quarter 2026 was a defining quarter for Agenus (AGEN) and for BOT and BAL,” said Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. “We saw continued…
Agenus provides 2026 strategic priorities
The company said, “2026 Strategic Priorities: Support responsible authorized access through France’s AAC framework and paid named-patient programs in select countries, with BAP Pharma serving as globa...
Agenus announces conclusion of SEC investigation with no enforcement action
The company said, “On May 4, 2026, the U.S. Securities and Exchange Commission informed Agenus (AGEN) that it has concluded its investigation as to the Company and does not intend…